The FRG1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte cell line, engineered for loss-of-function studies of the FRG1 gene. This polyclonal model provides a heterogeneous pool of cells carrying targeted disruptions in FRG1, enabling robust analysis of gene function without clonal isolation artifacts. As a knockout resource, it serves as a versatile tool for investigating FRG1-dependent mechanisms in human immune cells, particularly in the context of B-cell biology and lymphoma.
The Raji cell line originates from a Burkitt’s lymphoma patient and is immortalized via Epstein-Barr virus transformation. These B lymphocytes retain key features of antigen-presenting cells, including robust immunoglobulin expression and active proliferative signaling. Widely employed in immunology and cancer research, Raji cells provide a well-characterized platform to examine oncogenic processes, antibody production, and immune response modulation, making them a suitable host for targeted gene disruption studies.
FRG1 functions as a pre-mRNA splicing factor associated with the spliceosome, where it regulates alternative splicing decisions. It directly interacts with core spliceosomal components including SMN, PRP8, and SF3B1, positioning it within the dynamic spliceosome and SMN complex networks. Downstream, FRG1 influences the alternative splicing of targets such as TNNT2 and MTMR1, thereby modulating transcript isoform expression. Mechanistically, disruption of FRG1 impairs splicing fidelity, leading to altered exon usage and potential dysregulation of B-cell-specific transcripts, which may perturb normal lymphocyte functions and contribute to disease pathogenesis.
In the Raji B-cell context, FRG1 knockout is predicted to disturb the finely tuned splicing programs essential for antibody production and immune signaling. Given the interplay between splicing regulation and lymphoma progression, this model offers a relevant system to study how splicing aberrations drive malignant phenotypes. The model is particularly valuable for exploring the molecular underpinnings of FRG1-related disorders such as facioscapulohumeral muscular dystrophy, where splicing misregulation is implicated, and for dissecting the role of FRG1 in lymphomagenesis and B-cell survival pathways.
Researchers can utilize this polyclonal knockout population to investigate FRG1’s contribution to alternative splicing dynamics using techniques like RNA-seq, RT-qPCR for splice variants, and co-immunoprecipitation of spliceosomal complexes. Functional studies may include proliferation and apoptosis assays, drug sensitivity screens, and analysis of B-cell receptor signaling. The model is suited for uncovering splicing-dependent vulnerabilities in lymphoma and for testing therapeutic interventions targeting splicing machinery. For additional product specifications or support, please contact Ascent Research.
